Gyrate and Stargardt's Diseases: Symptoms, Risks, and Prevention

Q: Gyrate and Stargardt's Diseases: Symptoms, Risks, and Prevention

Hello Sir： <br>Gyrate Atrophy： This is a bilateral, progressive degenerative disease of the retina (retinal choroid). <br>Patients typically begin to exhibit symptoms around the age of 20, characterized by night blindness, constricted visual fields, and decreased vision. <br>It i

1. Gyrate Atrophy 2. Stargardt Disease

Dear Dr.
Yang,
1.
Gyrate Atrophy: This condition is characterized by progressive degeneration of the retina, leading to symptoms such as night blindness, peripheral vision loss, and eventual central vision loss.
Patients may also experience changes in color vision.
The disease is caused by a deficiency of the enzyme ornithine aminotransferase, leading to elevated levels of ornithine in the blood.
Prevention is limited, but managing dietary intake of arginine and ensuring regular eye examinations can help monitor the condition.
2.
Stargardt's Disease: This is a form of inherited macular degeneration that typically presents in childhood or adolescence.
Symptoms include blurred vision, difficulty seeing in low light, and a central scotoma (a blind spot in the center of vision).
The disease is caused by mutations in the ABCA4 gene, leading to the accumulation of toxic substances in the retina.
While there is no known prevention, maintaining a healthy lifestyle and protecting the eyes from excessive UV exposure may be beneficial.
I apologize for taking up your valuable time.

Cai, 40~49 year old female. Ask Date: 2007/03/01

Dr. Liu Jingxian reply Ophthalmology

Hello Sir:
Gyrate Atrophy: This is a bilateral, progressive degenerative disease of the retina (retinal choroid).
Patients typically begin to exhibit symptoms around the age of 20, characterized by night blindness, constricted visual fields, and decreased vision.
It is associated with a deficiency of a metabolic enzyme (mitochondrial matrix enzyme, ornithine aminotransferase) and is often accompanied by high myopia and cataracts.
It is an autosomal recessive genetic disorder linked to chromosome 10.
Stargardt’s Disease: This is one of the most common degenerative diseases of the macula, characterized by pigmentary changes in the posterior pole of both eyes.
Symptoms usually begin around the ages of 10 to 20, with no gender differences observed.
Features include bilateral vision loss, which typically continues to deteriorate, often resulting in vision below 0.1 by around the age of 30.
It is an autosomal recessive genetic disorder associated with chromosome 1p.
When the manifestation of hereditary diseases is related to chromosomes, it is generally not preventable in advance, and there are currently no effective treatment methods available.
Wishing you good health,
Taiwan e-Learning Academy, Department of Ophthalmology, Taipei City Hospital, Renai & Zhongxing Branches,
Dr.
Liu Jing-Hsi, March 2, 2007.

Reply Date: 2007/03/01

More Info

Gyrate Atrophy and Stargardt's Disease are both hereditary retinal disorders that primarily affect vision, but they have distinct characteristics, symptoms, and underlying mechanisms.

Gyrate Atrophy
Symptoms:
Gyrate Atrophy, also known as Gyrate Disease, typically manifests in early adulthood, around the age of 20. The symptoms include:
- Night Blindness: Difficulty seeing in low-light conditions is often one of the first signs.

- Progressive Vision Loss: Patients experience a gradual decline in visual acuity, leading to significant vision impairment over time.

- Peripheral Vision Loss: The visual field may narrow, resulting in tunnel vision.

- High Myopia: Many patients also develop severe nearsightedness.

- Cataracts: The development of cataracts is common in individuals with this condition.

Pathophysiology:
Gyrate Atrophy is caused by a deficiency in the enzyme ornithine aminotransferase, which is involved in the metabolism of the amino acid ornithine. This deficiency leads to the accumulation of ornithine, resulting in retinal degeneration. The condition is inherited in an autosomal recessive pattern and is linked to mutations on chromosome 10.

Prevention:
Currently, there are no known preventive measures for Gyrate Atrophy since it is a genetic disorder. However, early diagnosis and management of symptoms can help improve the quality of life. Regular eye examinations and genetic counseling may be beneficial for affected individuals and their families.

Stargardt's Disease
Symptoms:
Stargardt's Disease is the most common form of inherited macular degeneration, typically presenting in childhood or early adulthood (ages 10-20). Symptoms include:
- Central Vision Loss: Patients often experience a gradual loss of central vision, which can severely affect reading and recognizing faces.

- Blind Spots: The development of blind spots in the central vision is common.

- Color Vision Deficiency: Some patients may notice changes in their ability to perceive colors.

- Difficulty in Low Light: Similar to Gyrate Atrophy, individuals may struggle with vision in dim lighting.

Pathophysiology:
Stargardt's Disease is primarily caused by mutations in the ABCA4 gene, which plays a crucial role in the visual cycle within photoreceptor cells in the retina. This leads to the accumulation of toxic substances, causing damage to the retinal cells, particularly in the macula, which is responsible for sharp central vision. The disease follows an autosomal recessive inheritance pattern and is linked to chromosome 1p.

Prevention:
Like Gyrate Atrophy, there are no known preventive strategies for Stargardt's Disease due to its genetic nature. Genetic counseling may be helpful for families with a history of the disease. Patients are encouraged to protect their eyes from UV light by wearing sunglasses and to maintain a healthy lifestyle, which may help slow the progression of the disease.

Conclusion
Both Gyrate Atrophy and Stargardt's Disease are serious genetic conditions that lead to significant visual impairment. While there are no preventive measures available, understanding the symptoms and seeking early intervention can help manage the conditions. Regular follow-ups with an ophthalmologist are crucial for monitoring the progression of these diseases and for exploring potential treatments or supportive therapies that may enhance the quality of life for affected individuals.

Similar Q&A

Understanding the Differences Between Three Rare Metabolic Disorders

1. Methylmalonic acidemia 2. Isovalerylic acidemia 3. Glutaric acidemia

Dr. Xu Jiaqi reply Rare Disease
1. Methylmalonic Acidemia (MMA): Under normal circumstances, propionic acid is rapidly metabolized into methylmalonic acid, which is then converted into succinic acid by the enzyme methylmalonyl CoA mutase (MMM). Succinic acid is further metabolized by other enzymes into carbon d...

Understanding Phytosterolemia: Is It the Same as Sitosterolemia?

Is phytosterolemia the same as sitosterolemia? How severe is phytosterolemia? Does it significantly increase the risk of death from cardiovascular diseases?

Dr. Jian Yingxiu reply Rare Disease
Hello, Yu Yi: Sitosterolemia, also known as phytosterolemia, is a rare lipid metabolism disorder that is inherited in an autosomal recessive manner. If left untreated, this condition can pose a threat of cardiovascular disease and death at a young age. Currently, the disease can ...

Understanding Persistent Hiccups: A Guide to Gastrointestinal Health Issues

I often feel anxious for no reason, and sometimes I experience sharp pain in my heart. I have occasional pain on the left side of my abdomen near the navel and a little below it. I have daily bowel movements, but sometimes I go 2-3 days without one. My limbs feel cold, yet at tim...

Dr. Lin Minghui reply Gastroenterology and Hepatology
Hello, I am unsure whether you are referring to hiccups or belching. Hiccups are involuntary contractions of the diaphragm and abdominal muscles that cause a sudden closure of the vocal cords, resulting in a characteristic "hic" sound. Belching, on the other hand, is th...

Understanding Glycogen Storage Disease Type VII: Symptoms, Treatment, and Prognosis

Glycogen storage disease type VII (GSD VII), also known as Tarui disease, can present with symptoms such as muscle weakness, exercise intolerance, and myoglobinuria, particularly during infancy. There is currently no cure for this condition, and treatment mainly focuses on managi...

Dr. Lin Qingyuan reply Rare Disease
Glycogen storage disease type VII, also known as Tarui's disease, is indeed a very rare condition. According to data from Europe and the United States, it predominantly occurs in individuals of Jewish descent, with an incidence of approximately 2.3 cases per 100,000 live bir...